Multiple Myeloma

The FDA has approved panobinostat in combination with bortezomib and dexamethasone for patients with previously treated multiple myeloma, based on findings from the PANORAMA-1 trial.

The treatment options for patients with relapsed/refractory multiple myeloma are expanding rapidly, notably through clinical trial evidence supporting a number of three-drug combination regimens, according to Sundar Jagannath, MD.

Sundar Jagannath, MD, director of the multiple myeloma program, professor of medicine (hematology and medical oncology), Tisch Cancer Institute at Mount Sinai School of Medicine, discusses the recent approval of lenalidomide as a therapy for patients with multiple myeloma.

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.

With the advent of safer and more effective treatments, early diagnosis of multiple myeloma (MM) has become an important goal.

Morie Gertz, MD, the chair of the Department of Medicine at the Mayo Clinic, discusses expanding treatment options for myeloma.

A supplemental New Drug Application has been submitted to the FDA for the full regulatory approval of carfilzomib as a treatment for patients with relapsed multiple myeloma.

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Results from a pair of phase II studies indicate that adding the immunomodulatory agent pomalidomide (Pomalyst) to multiple myeloma regimens improved outcomes for patients who have stopped responding to earlier treatments.

Clinicians who treat patients with multiple myeloma have witnessed a sea change in the past 15 years. Yet another revolution appears right around the corner.

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the use of monoclonal antibodies for the treatment of multiple myeloma.